MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer’s disease

BACKGROUND: Current approved drugs for Alzheimer’s disease (AD) only attenuate symptoms, but do not cure the disease. The pirinixic acid derivate MH84 has been characterized as a dual gamma-secretase/proliferator activated receptor gamma (PPARγ) modulator in vitro. Pharmacokinetic studies in mice sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Pohland, Maximilian, Pellowska, Maren, Asseburg, Heike, Hagl, Stephanie, Reutzel, Martina, Joppe, Aljoscha, Berressem, Dirk, Eckert, Schamim H., Wurglics, Mario, Schubert‐Zsilavecz, Manfred, Eckert, Gunter P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809956/
https://www.ncbi.nlm.nih.gov/pubmed/29433569
http://dx.doi.org/10.1186/s13195-018-0342-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809956/
https://www.ncbi.nlm.nih.gov/pubmed/29433569
http://dx.doi.org/10.1186/s13195-018-0342-6

Ejemplares similares